Repetitive Transcranial Magnetic Stimulation for Apathy Clinical Trial (REACT)

Status: Recruiting
Location: See location...
Intervention Type: Device, Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Apathy is a common, early, and disabling symptom in dementias and mild behavioural impairment such as Alzheimer's disease (AD) and is characterized by lack of interest and enthusiasm. Both repetitive transcranial magnetic stimulation (rTMS), a form of non-invasive brain stimulation, and methylphenidate, a medication, have been shown to improve apathy. This pilot study will investigate rTMS as a treatment for apathy in neurocognitive disorders and mild behavioural impairment in individuals receiving methylphenidate and individuals not receiving medication for apathy.

Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: f
View:

• mild or major neurocognitive disorder OR mild behavioural impairment

• Apathy for at least 4 weeks

• Stable dose of medication (\>4 weeks) that may affect cognition or behaviour

• Care partner who spends at least 10 hours a week with the subject

Locations
Other Locations
Canada
Sunnybrook Health Sciences Centre
RECRUITING
Toronto
Time Frame
Start Date: 2023-02-09
Estimated Completion Date: 2025-12-01
Participants
Target number of participants: 10
Treatments
Experimental: rTMS + methylphenidate
repetitive transcranial magnetic stimulation (rTMS) and methylphenidate
Experimental: rTMS only
repetitive transcranial magnetic stimulation (rTMS) only
Related Therapeutic Areas
Sponsors
Leads: Sunnybrook Health Sciences Centre

This content was sourced from clinicaltrials.gov